MMCM
CTXR icon

Murphy & Mullick Capital Management’s Citius Pharmaceuticals CTXR Stock Holding History

Murphy & Mullick Capital Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-160
Closed -$144 – 689
2026
Q1 		$144 Hold
160
– – ﹤0.01% 712
2025
Q4 		$124 Hold
160
– – ﹤0.01% 741
2025
Q3 		$251 Hold
160
– – ﹤0.01% 657
2025
Q2 		$254 Hold
160
– – ﹤0.01% 652
2025
Q1 		$238 Hold
160
– – ﹤0.01% 649
2024
Q4 		$640 Buy
+160
New +$1.08K ﹤0.01% 619

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM

Murphy & Mullick Capital Management's CTXR Position: Q2 2026 in Review

Murphy & Mullick Capital Management sold out of Citius Pharmaceuticals (CTXR) in Q2 2026, closing a stake of 160 shares — an estimated $144 sold.

Murphy & Mullick Capital Management first reported a position in CTXR in Q4 2024 and held it in 6 quarters. The position peaked at $640 in Q4 2024. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • Murphy & Mullick Capital Management reported no remaining Citius Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Murphy & Mullick Capital Management sold 160 Citius Pharmaceuticals shares in Q2 2026, an estimated $144.
  • Murphy & Mullick Capital Management first reported a position in Citius Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Murphy & Mullick Capital Management's Citius Pharmaceuticals position peaked at $640 in Q4 2024.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.